P2Y 12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions

It remains unclear whether P2Y inhibitor monotherapy preserves ischemic protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI). We sought to assess the effects of P2Y inhibitor monotherapy after 1-month to 3-month...

Celý popis

Podrobná bibliografie

Vydáno v:	Journal of the American College of Cardiology Ročník 81; číslo 6; s. 537
Hlavní autoři:	Gragnano, Felice, Mehran, Roxana, Branca, Mattia, Franzone, Anna, Baber, Usman, Jang, Yangsoo, Kimura, Takeshi, Hahn, Joo-Yong, Zhao, Qiang, Windecker, Stephan, Gibson, Charles M, Kim, Byeong-Keuk, Watanabe, Hirotoshi, Song, Young Bin, Zhu, Yunpeng, Vranckx, Pascal, Mehta, Shamir, Hong, Sung-Jin, Ando, Kenji, Gwon, Hyeon-Cheol, Calabrò, Paolo, Serruys, Patrick W, Dangas, George D, McFadden, Eùgene P, Angiolillo, Dominick J, Heg, Dik, Valgimigli, Marco
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 14.02.2023
Témata:	Aspirin Drug Therapy, Combination Dual Anti-Platelet Therapy Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Percutaneous Coronary Intervention - adverse effects Platelet Aggregation Inhibitors Purinergic P2Y Receptor Antagonists Treatment Outcome meta-analysis percutaneous coronary intervention complex PCI P2Y inhibitors DAPT
ISSN:	1558-3597
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!